AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01521390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo, no active ingredient
Study NCT01281644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser
Description: 810 nm diode laser
Study NCT02524392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Independent medical evaluation
Description: The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
Study NCT04519086 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Description: Low-dose computed tomography for suspected acute uncomplicated appendicitis in patients with BMI >30
Study NCT04519086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: All patients with BMI >30, who are diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
Study NCT00611858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT00611858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Study NCT00611858 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT00814294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule,0 units, quater in die (QID) for 18 weeks
Study NCT00814294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Description: Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
Study NCT00814294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Description: Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
Study NCT01187979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash incentives
Description: Cash incentives paid to learners for reaching pre-determined milestones
Study NCT01187979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills curriculum
Description: Standard department of education lifeskills curriculum
Study NCT01187979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life skills curriculum
Description: Standard department of education lifeskills curriculum
Study NCT01324271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Tympanostomy Tube Delivery system (TTDS)
Description: placement of tympanostomy tube under local anesthesia
Study NCT03592511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: WGPF-burger
Description: Volunteers consumed a WGPF-burger daily
Study NCT03592511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control-burger
Description: Volunteers consumed a Control-burger daily
Study NCT03592511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control-burger
Description: Volunteers consumed a Control-burger daily
Study NCT06099067 — intervention group
Intervention type: DRUG
Intervention: Canagliflozin
Description: Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
Study NCT06099067 — intervention group
Intervention type: DRUG
Intervention: DPP4 inhibitor
Description: DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
Study NCT06099067 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
Study NCT06099067 — intervention group
Intervention type: DRUG
Intervention: Saxagliptin
Description: Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
Study NCT06099067 — intervention group
Intervention type: DRUG
Intervention: 2nd generation Sulfonylurea
Description: 2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
Study NCT03854071 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intravenous fluid challenge
Description: Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
Study NCT04283448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Lentil
Description: Participants in the Lentil arm of the study will consume midday meals containing 0.66 cups of lentils seven days per week for 12 weeks.
Study NCT04283448 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants in the Control arm of the study will consume midday meals containing 0.00 cups of lentils seven days per week for 12 weeks.
Study NCT01368965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System treatment
Description: Ulthera® System treatment delivering focused ultrasound energy
Study NCT00387582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Description: Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
Study NCT00387582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Laser
Description: Argon laser at entry to trial and then per protocol for the duration of the study.
Study NCT00877331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention using motivational interviewing
Description: One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
Study NCT01000740 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EGFR Mutation Test
Description: Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
Study NCT01698294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Participants maintain usual diet and undergo clinical observation
Study NCT01698294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Given PO
Study NCT01698294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01698294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01698294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01698294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01000740 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ki-67 protein expression
Description: Ki-67 protein expression in tissue will be analysed by IHC method.
Study NCT04832828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Roth´s Test
Description: Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.
Study NCT04040751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-CITE
Description: The primary CARE-CITE components will be education via web platform. Carepartners complete 6 online CARE-CITE modules (15-30-minute sessions each). The modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
Study NCT04040751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The carepartner will receive a support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
Study NCT00762450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, Fluoride
Description: Rinse 3 times daily with assigned toothpaste slurry
Study NCT00762450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoride
Description: Rinse 3 times daily with assigned toothpaste slurry
Study NCT00762450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride, triclosan, amino acid
Description: Rinse 3 times daily with assigned toothpaste slurry
Study NCT01864239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicines Advice Service
Description: The intervention consists of:~1. Telephone consultations with a pharmacist~2. Follow-up tailored written information~3. A medicine reminder chart
Study NCT02001766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Study NCT00934284 — intervention group
Intervention type: OTHER
Intervention: Lumbar injection
Description: Patients are instructed to resume normal activity as tolerated.
Study NCT00934284 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation following lumbar injection
Description: Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
Study NCT03057353 — intervention group
Intervention type: DEVICE
Intervention: lumbar CT imaging
Description: Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
Study NCT01124760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
Study NCT01124760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Orally, daily beginning on Day 4 for 14 consecutive days
Study NCT01124760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
Study NCT02453581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 Powder for Oral Suspension
Study NCT00744484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in water
Description: 45 minutes interval training in water, submaximal intensity, twice a week
Study NCT00744484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on land
Description: 45 minutes interval training on land, submaximal intensity, twice a week
Study NCT02652741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Orodispersible Minitablet
Description: 8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
Study NCT03585582 — intervention group
Intervention type: OTHER
Intervention: Prospective follow-up
Description: This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
Study NCT01302314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal management training (GMT)
Description: Fourteen hours of GMT during a time period of three months.
Study NCT02398318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)
Description: High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
Study NCT02398318 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Bilateral Nucleus Accumbens DBS
Description: DBS system switched off.
Study NCT04177069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Visucomplex Plus
Description: capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
Study NCT03109990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in the experimental group will receive Dexmedetomidine during surgery.
Study NCT03109990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in the control group will receive saline but not Dexmedetomidine during surgery.
Study NCT01231061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: •24 Gy in 3 fractions to cover at least 90% of the defined target volume
Study NCT02782169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
Study NCT02782169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule with excipient to match Pregabalin
Study NCT01937052 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
Study NCT01937052 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient-reported outcomes
Description: Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
Study NCT00558311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Intravenous clazosentan administered by continuous infusion at 5 mg/h
Study NCT00558311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by continuous infusion matching clazosentan administration
Study NCT03731689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine lavage therapy
Description: Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
Study NCT03731689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine gel-injection therapy
Description: Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
Study NCT00035529 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.
Study NCT00035529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS 188667 (Abatacept)
Description: Vial, i.v infusion, 2mg/kg, Days 1 \& 15 then monthly, 10 months.
Study NCT01231061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: 16 Gy in 1 fraction to cover at least 90% of the defined target volume
Study NCT01636297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced exercise
Description: Exercise on a stationary cycle that was controlled by a motor, to augment voluntary cycling rate by 35%. Intervention was administered 3 times per week for 8 weeks
Study NCT01636297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary exercise
Description: Exercise on a stationary cycle without motor assistance. Intervention was administered 3 times per week for 8 weeks
Study NCT03077997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Diabetes
Description: Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, \& diabetes distress in people with type 2 diabetes mellitus.
Study NCT04228510 — intervention group
Intervention type: PROCEDURE
Intervention: 2D speckle tracking echocardiography
Description: Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs).
Study NCT04467697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOV2012-F1
Description: Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU
Study NCT00035529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS 188667 (Abatacept)
Description: Vial, i.v infusion, 10 mg/kg, Days 1 \& 15 then monthly, 10 months.
Study NCT02347020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Sleep/ Normal Meal
Description: The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
Study NCT02347020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Sleep/ Late Meal
Description: The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
Study NCT03352661 — intervention group
Intervention type: OTHER
Intervention: Collect retrospectively data
Description: Collect retrospectively data
Study NCT01553578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01553578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01553578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: Receive healing touch therapy
Study NCT01553578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive healing touch therapy
Study NCT01553578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive guided imagery audiotapes
Study NCT01553578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Receive standard care
Study NCT02801916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 0 grams oat bran
Description: 200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
Study NCT02801916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 4.5 grams oat bran
Description: 200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
Study NCT02801916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 13.6 grams oat bran
Description: 200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread